Skip to content
AnimalUltra-potent frog-derived mu-opioid peptide

Dermorphin

Also indexed as Demorphin, H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2

Dermorphin is a naturally occurring heptapeptide opioid first isolated from the skin secretions of South American phyllomedusa frogs. It binds with extraordinarily high selectivity and affinity to mu-opioid receptors, producing potent analgesic and sedative effects estimated to be 30–40 times more potent than morphine on a molar basis. Its unique structure incorporates a D-amino acid (D-Ala), which confers resistance to enzymatic degradation and prolongs its biological activity.

Overview

Systemically, dermorphin demonstrates rapid CNS penetration with supraspinal and spinal analgesic activity mediated through MOR populations in the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and dorsal horn laminae I/II. It modulates the HPA axis via opioidergic inhibition of CRH release and influences dopaminergic reward circuitry through disinhibition of VTA dopamine neurons. Cardiovascular effects include MOR-mediated bradycardia and vasodilation. Gastrointestinal effects (constipation, reduced motility) arise from peripheral MOR activation in the enteric nervous system. Tolerance develops via receptor desensitization (GRK-mediated phosphorylation and β-arrestin recruitment), receptor internalization, and compensatory upregulation of adenylyl cyclase.

Proposed mechanism

Dermorphin acts as a highly selective, full agonist at mu-opioid receptors (MOR), activating Gi/Go protein signaling cascades that inhibit adenylyl cyclase, reduce cAMP levels, open inwardly rectifying K⁺ channels, and suppress voltage-gated Ca²⁺ channels, collectively hyperpolarizing neurons and suppressing nociceptive transmission. The presence of D-alanine at the second position renders it resistant to peptidase cleavage compared to endogenous opioid peptides, extending its half-life and potency. This receptor engagement in both spinal and supraspinal pain pathways accounts for its profound analgesic effect.

What the evidence supports

Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Graded Animal

Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Dermorphin and deltorphins: extraordinary peptides from frog skin

    · Erspamer V, Peptides Journal · 1992

  2. [2]

    The opioid peptides of the skin of Phyllomedusa sauvagei

    · Montecucchi PC et al., International Journal of Peptide and Protein Research 17(3):316-321 · 1981

  3. [3]

    Structure-activity relationships of dermorphin analogs

    · Lazarus LH et al., Pharmacological Reviews · 2000

  4. [4]

    Detection of dermorphin in equine plasma and urine by LC-MS/MS

    · Stanley SD et al., Drug Testing and Analysis · 2013

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

ACTH 1-39

Clinical

Full-length adrenal hormone with broad receptor activity

ACTH 1-39 is the full-length, biologically active form of adrenocorticotropic hormone, a 39-amino acid peptide naturally secreted by the anterior pituitary gland. It primarily stimulates the adrenal cortex to produce cortisol, aldosterone, and adrenal androgens. Beyond adrenal signaling, ACTH 1-39 exerts direct effects on the brain, immune system, and peripheral tissues via melanocortin receptors.

0 RCT · 0 human · 0 preclinical

Immune

Adamax

Anecdotal

Nootropic peptide blend for cognition and mood

Adamax is a research peptide blend reported to combine nootropic and neuroprotective peptide components aimed at enhancing cognitive function, mood stability, and neural recovery. It is marketed primarily for its potential effects on dopaminergic and serotonergic signaling pathways. Evidence is largely limited to preclinical and anecdotal sources, with no published human clinical trials specific to the Adamax formulation.

0 RCT · 0 human · 0 preclinical

cognition

ARA290 (Cibinetide)

Human-limited

Tissue-protective peptide for nerve repair and inflammation

ARA290, also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the helix B surface peptide of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis. It is designed to harness the tissue-protective and anti-inflammatory properties of EPO while avoiding its hematopoietic side effects. Clinically, it has been investigated for neuropathic pain, small fiber neuropathy, and inflammatory conditions such as sarcoidosis.

0 RCT · 0 human · 0 preclinical

Immune